URGNUroGen Pharma Ltd.
Pharmaceutical Preparations
- Revenue
- $110M
- 21% YoY
- Operating margin
- -113.7%
- 6.2% YoY
- EBITDA
- −$125M
- 29% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $121M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired11% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $48M | $64M | $83M | $90M | $110M | 21% |
| Operating income | −$92M | −$79M | −$66M | −$97M | −$125M | 29% |
| Net income | −$111M | −$110M | −$102M | −$127M | −$153M | 21% |
| Operating cash flow | −$85M | −$88M | −$76M | −$97M | −$162M | 68% |
| Capex | $752K | $254K | $194K | $295K | $289K | 2.0% |
| Stock-based comp | $23M | $11M | $9M | $13M | $12M | 8.8% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $183K · 3
- Net
- −$183K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $12M | 264 | — |
| FY2024 | $4M | $2M | 120 | — |
| FY2023 | $5M | $6M | 169 | — |